{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:31:44Z","timestamp":1787315504056,"version":"build-2736575974"},"reference-count":68,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CMAR"],"DOI":"10.2147\/cmar.s372237","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:40Z","timestamp":1689897640000},"page":"741-751","source":"Crossref","is-referenced-by-count":14,"title":["Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody"],"prefix":"10.2147","volume":"Volume 15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1668-9829","authenticated-orcid":true,"given":"Darren","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv"},{"key":"ref2","unstructured":"European medicines agency: tecvayli (teclistamab). Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecvayli. Accessed December 19, 2022."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"ref4","unstructured":"FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma. Accessed December 18, 2022."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e306","DOI":"10.1038\/bcj.2015.32","volume":"5","author":"Dosani","year":"2015","journal-title":"Blood Cancer J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/bjh.17805","volume":"196","author":"Swan","year":"2022","journal-title":"Br J Haematol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J Exp Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.18632\/oncotarget.27792","volume":"11","author":"Verkleij","year":"2020","journal-title":"Oncotarget"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1182\/blood-2020-138831","volume":"136","author":"Garfall","year":"2020","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1182\/blood-2022-159711","volume":"140","author":"Searle","year":"2022","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood-2021-148723","volume":"138","author":"Rodriguez-Otero","year":"2021","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"10148","DOI":"10.1182\/blood-2022-160173","volume":"140","author":"Krishnan","year":"2022","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"10073","DOI":"10.1182\/blood-2022-163733","volume":"140","author":"Lancman","year":"2022","journal-title":"Blood"},{"key":"ref19","first-page":"697","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood J Am Soc Hematol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1182\/blood-2022-159381","volume":"140","author":"Trudel","year":"2022","journal-title":"Blood"},{"key":"ref21","first-page":"8012","volume":"supplement 16","author":"van de Donk","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"ref23","volume-title":"Matching-Adjusted Indirect Comparison (MAIC) of Teclistamab (Tec) versus Selinexor-Dexamethasone (Sel-Dex) for the Treatment of Patients (Pts) with Triple-Class Exposed (TCE) Relapsed\/Refractory Multiple Myeloma (RRMM)","year":"2022"},{"key":"ref24","volume-title":"Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab (Tec) versus Belantamab Mafodotin (Belamaf) for the Treatment of Patients (Pts) with Triple-Class Exposed (TCE), Relapsed\/Refractory Multiple Myeloma (RRMM)","year":"2022"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"12483","DOI":"10.1182\/blood-2022-159806","volume":"140","author":"Pan","year":"2022","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.1182\/blood-2018-99-112258","volume":"132","author":"Goldsmith","year":"2018","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.5045\/br.2016.51.3.193","volume":"51","author":"Kim","year":"2016","journal-title":"Blood Res"},{"key":"ref28","volume-title":"Real-World Outcomes with Panobinostat in Patients with Penta-and Quad-Refractory Multiple Myeloma","year":"2017"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1158\/1078-0432.CCR-19-2111","volume":"26","author":"Cohen","year":"2020","journal-title":"Clin Cancer Res"},{"key":"ref32","first-page":"2578","volume":"126","author":"Zugmaier","year":"2015","journal-title":"Blood J Am Soc Hematol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-015-1261-6","volume":"15","author":"Osborne","year":"2015","journal-title":"BMC Cancer"},{"key":"ref34","unstructured":"European Medicines Agency. Carvykti. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/carvykti. Accessed January 28, 2023."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"ref37","first-page":"842","volume":"2022","author":"Martin","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","volume":"16","author":"Lin","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"8012","DOI":"10.1200\/JCO.2023.41.16_suppl.8012","volume":"16","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"10036","DOI":"10.1182\/blood-2022-169836","volume":"140","author":"Sharma","year":"2022","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.3390\/cancers14061501","volume":"14","author":"Sharma","year":"2022","journal-title":"Cancers"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1080\/10428194.2019.1697814","volume":"61","author":"Nahas","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1182\/blood-2022-165646","volume":"140","author":"Thibaud","year":"2022","journal-title":"Blood"},{"key":"ref44","unstructured":"Goodman A. Patients with multiple myeloma may face CAR T-cell shortages. Availble from: https:\/\/ascopost.com\/issues\/september-25-2022\/patients-with-multiple-myeloma-may-face-car-t-cell-shortages\/. Accessed February 15, 2023."},{"key":"ref45","volume-title":"Ethical Challenges with CAR T Slot Allocation with Idecabtagene Vicleucel Manufacturing Access","year":"2022"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jtct.2023.01.012","volume":"29","author":"Kourelis","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41409-022-01905-1","volume":"58","author":"Al Hadidi","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/cncr.34756","volume":"129","author":"Martin","year":"2023","journal-title":"Cancer"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.clml.2020.04.020","volume":"20","author":"Jatiani","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/blood-2021-150592","volume":"138","author":"Wong","year":"2021","journal-title":"Blood"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-021-00209-2","volume":"10","author":"Zhang","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"ref52","first-page":"705","volume":"2020","author":"Si","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"ref53","first-page":"1426","volume":"30","author":"Nishimoto","year":"2003","journal-title":"J Rheumatol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"e000621","DOI":"10.1136\/jitc-2020-000621","volume":"8","author":"Kauer","year":"2020","journal-title":"J Immunother Cancer"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"e003847","DOI":"10.1136\/jitc-2021-003847","volume":"10","author":"Wehrli","year":"2022","journal-title":"J Immuno Can"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"5073","DOI":"10.1182\/blood-2022-169809","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1182\/blood.V128.22.652.652","volume":"128","author":"Kenderian","year":"2016","journal-title":"Blood"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4049\/jimmunol.1302282","volume":"192","author":"Johnson","year":"2014","journal-title":"J Immunol Res"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"S312","DOI":"10.1016\/j.bbmt.2019.12.389","volume":"26","author":"Harris","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref61","volume-title":"The EBMT\/EHA CAR-T Cell Handbook","year":"2022"},{"key":"ref62","first-page":"662","volume":"132","author":"Nellan","year":"2018","journal-title":"Blood J Am Soc Hematol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/TCRM.S150524","volume":"Volume 15","author":"Riegler","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13613-022-01036-2","volume":"12","author":"Valade","year":"2022","journal-title":"Ann Intensive Care"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"20406207221100659","DOI":"10.1177\/20406207221100659","volume":"13","author":"Steinbach","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"ref66","volume-title":"First Results from the Redirectt-1 Study with Teclistamab (Tec)+ Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM)","year":"2023"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"7289","DOI":"10.1182\/blood-2022-159756","volume":"140","author":"Zamagni","year":"2022","journal-title":"Blood"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/S2152-2650(22)00347-0","volume":"22","author":"Mateos","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Cancer Management and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=91361","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=91361","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:53Z","timestamp":1689897653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/teclistamab-for-multiple-myeloma-clinical-insights-and-practical-consi-peer-reviewed-fulltext-article-CMAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":68,"URL":"https:\/\/doi.org\/10.2147\/cmar.s372237","relation":{},"ISSN":["1179-1322"],"issn-type":[{"value":"1179-1322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}